Catalyst Event
Innovent Biologics Inc (1801) · Other
From Akros SCHK HK-Korea Biotech Index (ASHKBIO)
4/28/2026, 12:00:00 AM
China's CDE proposed including IBI363, a first-in-class PD-1/IL-2α bispecific antibody, for breakthrough therapy designation for the treatment of advanced MSS/pMMR colorectal cancer. This regulatory progress is estimated to have a medium market impact (≥5%).
Korean Translation
중국 국가약품감독관리국(CDE)이 세계 최초(First-in-class) PD-1/IL-2α 이중 특이성 항체인 IBI363을 진행성 MSS/pMMR 유형 대장암 치료를 위한 혁신 치료제로 지정할 것을 제안함. 이러한 규제 진전은 5% 이상의 중간 수준 시장 영향력을 미칠 것으로 예상됨.
Related Recent Events
Samchundang Pharm Co Ltd (000250) · Other
Extraordinary shareholders' meeting to appoint a former Financial Supervisory Service (FSS) official as a new outside director on June 30, 2026. Low importance is estimated as board changes typically have minimal immediate price impact, scheduled.
6/30/2026, 12:00:00 AM
LigaChem Biosciences Inc (141080) · Earnings Release
The company's quarterly earnings report is scheduled for May 18, 2026; a 5-10% price impact is estimated based on historical volatility, scheduled.
5/18/2026, 12:00:00 AM
Samchundang Pharm Co Ltd (000250) · Earnings Release
Q1 2026 earnings release on May 18, 2026. Low importance is estimated as the announcement of the release date itself usually results in minimal price movement, scheduled.
5/18/2026, 12:00:00 AM
Celltrion Inc (068270) · Earnings Release
Celltrion is scheduled to announce its Q1 2026 earnings on May 8, 2026. Analysts forecast consolidated sales of approximately 1.12 trillion KRW and an operating profit of around 314 billion KRW, which is estimated to have a medium market impact (≥5%) scheduled.
5/8/2026, 12:00:00 AM
Samsung Biologics Co Ltd (207940) · Other
The company's labor union has threatened its first-ever general strike to begin on May 1, 2026, following the breakdown of wage negotiations. Analysts forecast a price impact of over 10% due to significant operational risks, expected.
5/1/2026, 12:00:00 AM
Celltrion Inc (068270) · Other
Celltrion applied for marketing authorization to the European Medicines Agency (EMA) for 'Herzuma SC', a subcutaneous formulation of its breast cancer biosimilar Trastuzumab, on April 30, 2026. This first-in-class formulation is estimated to have a high market impact (≥10%) due to its significant competitive advantage.
4/30/2026, 12:00:00 AM